Ishikawa Tsuyoshi, Hamamoto Kaori, Sasaki Ryo, Nishimura Tatsuro, Matsuda Takashi, Iwamoto Takuya, Takami Taro, Sakaida Isao
Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube-Yamaguchi, 7558505, Japan.
Hepatol Res. 2020 Oct;50(10):1201-1208. doi: 10.1111/hepr.13545. Epub 2020 Jul 15.
This study describes a case of hepatitis C virus-related decompensated cirrhosis with portal-systemic liver failure and refractory encephalopathy. It was successfully managed with a combination of interventional radiology and pharmacotherapy, to improve hepatic function, including hyperammonemia and to control portal-splenic venous hemodynamics with hepatic venous pressure gradient (HVPG) monitoring. A man in his late 50s presented with a Child-Pugh score of 13, Model for End-Stage Liver Disease-sodium (MELD-Na) score of 19 and blood ammonia level of 185 μg/dL. He underwent balloon-occluded retrograde transvenous obliteration (BRTO) followed by partial splenic embolization (PSE) and non-selective beta-blocker (NSBB) administration. BRTO induced drastic changes in the portal-splenic venous hemodynamics, resulting in dramatically improved hepatic function and reduced hyperammonemia. However, the procedure resulted in increased HVPG from 13.6 mmHg at baseline to 23.5 mmHg at 1-month post-BRTO, accompanied by ascites retention and development of portal hypertensive gastropathy. Thereafter, PSE was performed, followed by NSBB administration, to control the elevated portal venous pressure following BRTO. Postoperatively, the patient's ascites and portal hypertensive gastrophy improved after splenic artery embolization, which eventually disappeared after the additional administration of NSBBs 1 month later. The HVPG finally decreased to 16.9 mmHg; the Child-Pugh score, MELD-Na score and blood ammonia level improved to 7, 11 and 22 μg/dL, respectively, after all therapies. BRTO significantly improved the symptoms of portal-systemic liver failure with refractory encephalopathy. PSE and NSBB administration could contribute to additional amelioration of hepatic function and successful management of complications induced by portal hemodynamic changes following BRTO.
本研究描述了一例丙型肝炎病毒相关失代偿性肝硬化合并门体性肝衰竭及难治性肝性脑病的病例。通过介入放射学与药物治疗相结合的方法成功进行了管理,以改善肝功能,包括高氨血症,并通过肝静脉压力梯度(HVPG)监测来控制门脾静脉血流动力学。一名50多岁的男性患者,其Child-Pugh评分为13分,终末期肝病钠模型(MELD-Na)评分为19分,血氨水平为185μg/dL。他接受了球囊闭塞逆行静脉栓塞术(BRTO),随后进行了部分脾栓塞术(PSE)并给予非选择性β受体阻滞剂(NSBB)。BRTO引起了门脾静脉血流动力学的剧烈变化,导致肝功能显著改善且高氨血症减轻。然而,该操作导致HVPG从基线时的13.6 mmHg升高至BRTO术后1个月时的23.5 mmHg,同时伴有腹水潴留和门静脉高压性胃病的发生。此后,进行了PSE,随后给予NSBB,以控制BRTO后门静脉压力的升高。术后,患者的腹水和门静脉高压性胃病在脾动脉栓塞术后有所改善,1个月后额外给予NSBBs后最终消失。HVPG最终降至16.9 mmHg;经过所有治疗后,Child-Pugh评分、MELD-Na评分和血氨水平分别改善至7分、11分和22μg/dL。BRTO显著改善了合并难治性肝性脑病的门体性肝衰竭症状。PSE和NSBB的应用有助于进一步改善肝功能,并成功管理BRTO后门血流动力学变化引起的并发症。